Houston-based Bio-Path Holdings, Inc. is once again preparing to report key data from clinical trials involving its liposomal delivery technology for nucleic acid cancer drugs, announcing that MD Anderson‘s Dr. Jorge Cortes, deputy chair and professor of medicine in the Department of Leukemia, will conduct the poster presentation during this year’s 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.
Dr. Cortes, who was featured in the news back in August in connection with Bio-Path’s announcement that the company’s lead product candidate Liposomal Grb -2 (BP-100-1.01) is capable of inhibiting the disease causing targets in several blood cancers, will now, “. . . highlight an assay that was developed to measure inhibition of the disease target protein Grb-2 in patients’ peripheral blood samples from the on-going Phase I trial,” according to a recent press release.
Read recent news articles about Bio-Path Holdings here:
[feed url=”http://bionews-tx.com/news/news-tags/bio-path-holdings/feed” number=”5″ ]
Bio-Path’s research findings have revealed that the adaptor protein Growth Receptor Bound protein-2 (Grb-2) is used by oncogenic tyrosine kinases, which stokes cancer progression, making it critical to cancer cell signaling. As a result, Bio-Path researchers theorize that if a treatment can effectively suppress the function or expression of Grb-2, in would in turn interrupt its vital signaling function, thus disrupting the progression of cancer. According to Bio-Path, “BP-100.1.01 is a neutral-charge, liposome-incorporated antisense drug substance designed to inhibit Grb-2 expression,” which effectively triggers this process.
Here are the details for Dr. Cortes’ Poster Presentation at the Annual Meeting of the American Society of Hematology:
Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In
Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)
Session Name: 615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster IIDate: Sunday, December 8, 2013Presentation Time: 6:30 PM – 8:30 PM, Central Standard Time:Location: Ernest N. Morial Convention Center, Hall E